Physician's Perspectives

Physician roundtable: Experiences with minimally invasive treatments for BPH

Headshot of Dean Elterman M.D., M.Sc., F.R.C.S.C.

Dean Elterman, M.D., M.Sc., F.R.C.S.C.a

Headshot of James E. Fagelson, M.D., F.A.C.S.

James E. Fagelson, M.D., F.A.C.S.b

Headshot of Shammai Rockove, M.D., F.A.C.S.

Shammai Rockove, M.D., F.A.C.S.c

Headshot of Justin Cohen, M.D.

Justin Cohen, M.D.d

Headshot of Anthony Golio, M.D., F.A.C.S.

Anthony Golio, M.D., F.A.C.S.e

Editorial commentary

The sentiments expressed within this article are representative of the opinions and experiences of the respective physicians. Drs. Elterman, Fagelson, Cohen and Golio are Boston Scientific consultants and were compensated. Physician experience and patient responses can and do vary.

When it comes to minimally invasive treatment (MIT) for benign prostatic hyperplasia (BPH), urologists are looking not only for good short-term results but also for long-term durability. Two MITs have recently come into prominence: UroLift™ Prostatic Urethral Lift System and Rezūm™ Water Vapor Therapy.

The UroLift System is an in-office, minimally invasive solution that involves the use of implants to hold open the obstructed pathway that’s blocking urine flow. Rezūm Therapy is an in-office, minimally invasive procedure that uses water vapor thermal therapy (steam) to shrink the prostate. Both procedures have long-term durability data up to five years.1,2

Recently, Dr. Dean Elterman, Assistant Professor, University of Toronto and Attending Urologist, University Health Network, Toronto, Canada, moderated a virtual roundtable discussion with four other urologists to explore their experiences with the UroLift System and Rezūm Therapy.

Conclusion

The urologists in the roundtable discussion acknowledge the popularity of UroLift; however, they express concerns about durability. Despite some drawbacks, such as the temporary need for a catheter and potential ejaculatory dysfunction, they have found that Rezūm Therapy improves BPH symptoms and quality of life for patients, and it has the lowest five-year retreatment rate of BPH MITs.1

Related content

Be the first to know.

Stay up-to-date with the latest editorials from expert physicians.


aUrologist with the University Urology Associates in Toronto and is on the faculty at the University of Toronto’s Division of Urology. Elterman’s clinical and research interests include male health, voiding dysfunction and reconstruction including BPH, incontinence, and sexual dysfunction.
bUrologist with the Urology Associates in Denver. Highly experienced in laser and robotics surgery, Fagelson has expertise in treating prostate disease, including enlarged prostate (BPH) and prostate cancer.
cUrologist with the Center for Men’s and Women’s Urology in Gresham, OR. Rockove also holds faculty positions at local medical schools and was previously the Director of the Providence Portland Continence Program.
dUrologist in Libertyville, IL, who is Executive Vice President and Chief Compliance Officer for Uropartners, LLC, in Chicago. Cohen has expertise in treating BPH, minimally invasive stone treatment, vasectomy, prostate cancer and robotic surgery.
eUrologist with Urology Services in Clarion, PA, with decades of diverse medical and teaching experience. Golio is affiliated with Clarion Hospital, Penn Highlands Brookville and other hospitals.

References

  1. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rezūm water vapor thermal therapy for treatment of moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021 Apr 19. Online ahead of print.
  2. Roehrborn CG, Barkin J, Gange SN, et al. Five-year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017 Jun;24(3):8802–13.
  3. Rezūm Instructions for Use.

Risks

Potential risks associated with Rezūm Water Vapor Therapy include but are not limited to dysuria, hematuria, hematospermia, decrease in ejaculatory volume, suspected urinary tract infection (UTI), urinary frequency, and retention or urgency. Refer to the Instructions for Use for a complete list of risks.

Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.


Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the use of referenced technologies but may not be appropriate for every patient or case. Decisions surrounding patient care depend on the physician’s professional judgment in consideration of all available information for the individual case.

Boston Scientific (BSC) does not promote or encourage the use of its devices outside their approved labeling. Case studies are not necessarily representative of clinical outcomes in all cases as individual results may vary.

Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.

Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.